AIMAR survey on COPD phenotypes
© Magnoni et al.; licensee BioMed Central Ltd. 2014
Received: 19 February 2014
Accepted: 26 February 2014
Published: 17 March 2014
COPD is characterized by considerable diversity in terms of clinical signs and symptoms, physiopathological mechanisms, response to treatment and disease progression. For this reason, the identification of different patient subgroups (or possible phenotypes) is important both for prognosis and for therapeutic objectives. Based on the foregoing, AIMAR has decided to conduct a survey on the perception of the prevalence of the different clinical COPD phenotypes/subtypes in the clinical practice of physicians who treat patients with chronic obstructive pulmonary disease, and on their therapeutic objectives.
The survey consisted of 19 multiple-choice questions, compiled through a form published online. All the data and answers entered into the system were checked for consistency and completeness directly online at the time they were entered, and each respondent could only complete the questionnaire once.
The survey took place from May through October 2012. A total of 1,434 questionnaires (60% of the sample approached) were eligible for analysis, broken down as follows: 537 pulmonologists, 666 general practitioners (GPs), 72 internal medicine specialists, 36 allergists, 30 geriatricians, 93 other specialists. The results show that a significant proportion of GPs (33%) identified more than 50 patients in their practices with a diagnosis of COPD. Although most patients are or have been in treatment with a long-acting bronchodilator, the most common reasons for seeing a GP or a specialist were exacerbations and worsening of the symptoms, suggesting the importance of an appropriate background therapy in order to reduce the risk of disease instability. The frequent exacerbator phenotype was the most commonly found phenotype in clinical practice (by 75% of specialists and 66% of GPs); patients with a prevalent phenotype of chronic bronchitis were reported more often by GPs, while specialists reported a higher number of patients with a prevalent phenotype of emphysema.
A medical history of exacerbations and the extent of deterioration of the spirometry parameters were considered to be the major indicators for COPD severity and clinical risk. In managing the frequent exacerbator phenotype, the therapeutic objectives – both for GPs and for specialists – included reducing airway inflammation, improving bronchial dilation, and reducing pulmonary hyperinflation. For this type of patients at high clinical risk, specialists selected a first-line therapeutic option based on a predetermined combination of an inhaled corticosteroid (ICS) and a long-acting β2-agonist bronchodilator (LABA) and a second-line three-drug therapy (combination of ICS and two long-acting bronchodilators), while GPs’ choices are more diversified, without a clear-cut prevalence of one type of treatment. In patients with COPD and concomitant cardiovascular diseases, frequently observed in clinical practice by all physicians, the combination of ICS and LABA was considered the first-choice option by the highest proportion of GPs (43%) and specialists (37%), while a smaller number of specialists (35%) opted for the long acting muscarinic antagonists (LAMA). Both GPs and specialists believe that therapeutic continuity is of primary importance for the achievement of clinical outcomes with all classes of drugs.
A good knowledge of COPD has been observed in a high percentage of GPs, indicating an increased awareness of this disease in Primary Health Care. The frequent exacerbator phenotype is viewed by all physicians as the most prevalent in clinical practice, bearing a high risk of hospitalization. For specialists, therapeutic measures aimed at reducing the number and severity of exacerbations are primarily based on the combination of inhaled corticosteroid and bronchodilator, presumably because of the complementary pharmacological action of its components, whereas while GPs’ choices tend to be more diversified. Adherence to medication regimens is of the essence for the achievement of clinical outcomes.
KeywordsCOPD Exacerbations Online survey Phenotypes
Chronic obstructive pulmonary disease (COPD) is a complex, multi-component disease with a significant heterogeneity with respect to clinical presentation (symptoms, exercise tolerance, exacerbation susceptibility), radiological features, mechanisms of airflow limitation and disease progression, independently of the degree of airflow limitation .
Within the scientific community there has been a growing interest in categorizing this clinical and physiopathological heterogeneity into COPD “phenotypes”. The concept of phenotype is not new: in the mid-20th century COPD was classified as “phenotype A”, characterized by findings of emphysema, and “phenotype B”, characterized by chronic bronchitis, on the basis of clinical, radiological and physiopathological evidence . These two types were the extremes of a spectrum and often coexist to different extent in most patients. In recent years the advances of imaging diagnostics (high resolution computerized tomography, MRI) have considerably fostered a renewed interest in the classification of patients by clinical-pathological phenotypes, which is driven by the development of new studies to define the clinical phenotypes of COPD [3–7].
An essential contribution to knowledge in this field came from the study of the ECLIPSE  cohort, one of the largest and best characterized within the scope of COPD studies: 2,180 patients and 566 controls, smokers and non-smokers, were followed up for three years in order to define clinically relevant COPD subtypes and to identify parameters and bio-markers able to predict disease progression. One of the first analyses  of the longitudinal data gathered from the ECLIPSE cohort led to the identification of a distinct COPD phenotype at higher risk of exacerbation (“frequent exacerbator”), which is stable over time, similar across GOLD stages, characterized by inherent susceptibility to triggers like viral infections, clinically predictable and identifiable through the clinical history. In fact, a medical history of exacerbations was found to be the predictive factor most closely correlated with their frequency.
More recently, it has been observed that the patient subgroup accounting for approximately 16% of the cohort had constantly elevated levels of markers of systemic inflammation, correlated with an increased risk of death and exacerbation compared to patients with less inflammation. It has been suggested that the constant presence of systemic inflammation, flared up by repeated exacerbations , identifies a new, distinct phenotype of COPD patient, who might be treated with specific therapeutic strategies .
The heterogeneity of COPD may make this disease very complex to manage, as the different phenotypes could have diverging prognosis or treatment needs. Hence the interest in investigating the perception and impact of the different COPD phenotypes in the clinical practice of physicians who treat patients with chronic obstructive pulmonary disease. On this basis, AIMAR (Interdisciplinary Scientific Association for the Study of Respiratory Diseases) decided to launch a survey on this specific subject, with the help of an unconditional contribution from GlaxoSmithKline, in order to collect information on the following main aspects:
Perception of the frequency of the different COPD phenotypes (frequent exacerbator, with prevalent emphysema, with prevalent chronic bronchitis, with marked reversibility).
Management of the different types of COPD patients.
On the basis of the objectives indicated above, the scientific committee that thought of the survey developed a questionnaire that acquired data through a form available online, which the respondents could complete at any time. The questionnaire included 19 multiple-choice questions and was addressed to the following specialists: pulmonologists, allergy specialists, geriatricians, internal medicine specialists and general practitioners. All the data and answers entered into the system were checked for consistency and completeness directly online at the time they were entered, and each respondent could only complete the questionnaire once. The data gathered in this way restored directly into a relational database (based on the proven open-sourceMySQL technology), and therefore were immediately available for queries even while the survey was still ongoing. The access to the data, mediated by a back office query and reporting system, allowed constant monitoring of the correct conduct of the survey; it was also possible to extract and check data on smaller data sets.
Of the 1,516 questionnaires collected (corresponding to 63,4% responders), 82 were incomplete or erroneously compiled, and therefore considered not valid, coming to a total of 1,434 questionnaires eligible for analysis (60% of the sample approached), broken down as follows: 537 pulmonologists, 666 general practitioners, 72 internal medicine specialists, 36 allergy specialists, 30 geriatricians, 93 other specialists (including anesthesiologists and resuscitators, cardiologists, ear, nose and throat specialists, allergy specialists, emergency physicians, physiatrists, oncologists, and thoracic surgeons).
As to the number of visits of individual patients per year, the results show a rather high frequency – at least three visits per year – for 85% of GPs (more than three visits per year in 60% of cases): the reasons of the physical examinations presumably range from disease monitoring to worsening of the symptoms or management of possible comorbidities. The majority of specialists see the same patient two or three times per year (Figure 2B).
Most frequent cause for patients to first see their GP or a specialist
Dyspnea & limitations
Disease other than COPD
Types of COPD patients or phenotypes
Prevalence of the different types of patients (phenotypes) in the COPD patient population treated by GPs and specialists
Frequent exacerbator phenotype
Predominant emphysema phenotype
Predominant chronic bronchitis phenotype
COPD with significant reversibility
Categorization of COPD patients: severity indicators, risk of hospitalization
Types of COPD patients considered at highest risk of hospitalization
Frequent exacerbator phenotype
Predominant emphysema phenotype
Predominant chronic bronchitis phenotype
COPD with significant reversibility
Risk of hospital.
Another important aspect in assessing the COPD patients’ clinical picture is the presence of comorbidities, particularly of a cardiovascular nature, widely recognized both by GPs and by specialists (data not shown).
The therapeutic approach: objectives and classes of drugs
The therapeutic choices of GPs are more diversified, although a higher proportion favors an ICS containing regimen (35% opt for the ICS + LABA combination, 21% for three-drug therapy), compared to individual bronchodilators (25% LABA or LAMA, 15% a combination of two bronchodilators). It should be noted, however, that one quarter of GPs opt for bronchodilator monotherapy even in patients at high risk of exacerbation (Figure 9B).
COPD prevalence data, in relation to a known chronic bronchitis or emphysema diagnosis, indicate that this disorder affects around 4-6% of the general population , corresponding to approximately 3 million patients in Italy. This figure almost certainly underestimates the real size of the problem: in Italy, like in the rest of the world, COPD is widely under-diagnosed, often goes untreated until the advanced stages, and appears to be a major issue even among young adult [32, 33].
Against this backdrop, the results of the survey indicate that a high percentage of GPs (approximately one third of them identified more than 50 of their patients with COPD), indicating an increased awareness of this disease in Primary Health Care.
Hopefully, this will result in greater attention to alarming symptoms and greater use of diagnostic tools, which would allow patients to be treated early on and to slow down their evolution towards disability. On the other hand, the fact that a significant percentage of GPs (44%) diagnosed with COPD fewer than 20 patients (much below all epidemiological data) suggests a need to continue to offer educational programs in this field. As it is well known, COPD can go undetected for a long time, because patients initially tend to minimize or ignore symptoms like cough and increased phlegm, which they may consider as a “normal” consequence of smoking, and get used to the difficulties caused by the disease by reducing their exercise. This is why they often first present for examination in an advanced stage of the disease . These considerations emphasize the strategic role of GPs in proactive case finding, using, among other means, specific questionnaires administered to patients at risk, such as smokers.
While a large majority of patients is or has been in treatment with a long-acting bronchodilator, the most common causes of the medical examination are exacerbations and worsening of the symptoms, both for GPs and for specialists: this confirms the importance of an appropriate background therapy in order to reduce the risk of disease instability and use of healthcare resources alongside with compliance to inhalation therapy. To note, in patients with chronic bronchial obstructive disease compliance with inhalation therapy is often low, and errors in the use of inhalators are very common [35–40]: in this regard, physicians can play an essential role in patient education on therapeutic adherence, including the correct use of devices, thus improving disease management .
Virtually all physicians, both GPs and specialists, believe that there are different types or phenotypes of patients. The “frequent exacerbator” phenotype is one of the most commonly seen both by GPs and specialists in everyday clinical practice, with an estimated prevalence of more than 30% of the COPD patient population according to over one third of the physicians. The patient phenotype with prevalence of chronic bronchitis is more commonly reported by GPs (estimated to be more than 30% by approximately half of the physicians), while the phenotype with prevalence of emphysema is more commonly reported by specialists. The fact that the type of patients with significant reversibility to the bronchodilation test is encountered rarely presumably reflects the infrequent use of spirometry. It should be specified that data recently emerged from the ECLIPSE study have demonstrated that in many COPD patients reversibility is not a stable characteristic, and therefore does not define a phenotype .
With regard to COPD staging, a medical history of exacerbations and the extent of deterioration of spirometry parameters are considered to be top indicators for COPD severity. A primary role is attributed to disease exacerbations particularly by specialists, in line with scientific evidence which has conclusively demonstrated that spirometry parameters alone (FEV1) do not reflect the complexity of the disease and are insufficient to classify its severity . In fact, the guidelines and recommendation documents advocate a multidimensional patient assessment, in which the measurement of bronchial obstruction is complemented with an evaluation of the risk of exacerbations and the presence of comorbidities [1, 25]. To note, the 2013 update of GOLD guide-lines indicate that even one hospitalization for COPD exacerbation should be considered high risk .
The frequent exacerbator phenotype is considered at highest risk of hospitalization by both categories of physicians. Furthermore, knowing the frequency of exacerbations is viewed as essential to determine the clinical risk: in this respect, it is interesting to note that most specialists – unlike GPs – indicate a clinical history of exacerbations as the predictive factor most closely correlated with their frequency, in line with the findings of the ECLIPSE study  and with evidence from everyday clinical practice. It is worth mentioning that a recent study has demonstrated prospectively that COPD patients are able to estimate accurately the frequency of the exacerbations they experienced during the previous year . The reliability and “strength” of their recollection allow the different types of patients – frequent exacerbators and non-frequent exacerbators - to be identified on the basis of medical history.
Another important aspect in assessing COPD patients’ clinical picture is the presence of comorbidities, particularly of a cardiovascular nature, widely recognized both by GPs and by specialists. The preliminary data of a cross-sectional European study have demonstrated that the prevalence of reduced air flow in a sample of 1,803 patients with cardiovascular disease treated on an outpatient basis is 30.6%; interestingly, only 29.4% of these had been previously diagnosed with COPD . Therefore, a reduced air flow compatible with COPD is commonly found and under-diagnosed in patients with cardiovascular conditions. The presence of comorbidities or complications is relevant in determining COPD evolution and prognosis: it is estimated that approximately 50% of COPD patients die of cardiovascular causes, and the risk of death and hospitalization is higher the more severe the airway obstruction, regardless of whether the patient is a smoker or a non-smoker [45, 46].
While recognizing the existence of different types or phenotypes of COPD patients, approximately half of the physicians believe that there is a standard pharmacological approach, which is effective for all patients. This approach is a combination of inhaled corticosteroid and bronchodilator, presumably because of the complementary pharmacological action of its components.
Taking therapeutic measures aimed at reducing the number and severity of exacerbations clearly results in savings in financial, social and health care resources . In the treatment of frequent exacerbators, both GPs and specialists indicate reduction of airway inflammation, bronchodilation and reduction of pulmonary hyperinflation, which is responsible for low tolerance to physical effort, as essential to achieve the therapeutic effect. Accordingly, for this type of patients at high clinical risk, specialists sculpt primarily for regimens containing inhaled corticosteroid in fixed combination with LABA (or a three-drug therapy in combination with two bronchodilators), in line with evidence reported by literature and incorporated into the guidelines, while GPs’ choices tend to be more diversified, without a clear-cut prevalence of one type of treatment.
In patients with COPD and other concomitant disorders, frequently of a cardiovascular nature, special attention should be given to treatment tolerability: a fixed ICS + LABA combination is the first-line option according to the highest proportion of GPs and specialists, while a fairly large number of specialists opt for LAMAs. It is worth recalling that long-term clinical studies conducted on large populations of patients, many of whom had cardiac disorders and were in treatment with anti-arrhythmic agents, demonstrated a good tolerability profile of the ICS + LABA combination, at cardiovascular [47, 48] as well as bone tissue level ; in general, the same can be said of long-acting bronchodilators [48, 50].
In the forms of asthma evolving towards permanent obstruction, typical of patients who persist in the habit of smoking, or in mixed or overlapping forms of asthma and COPD, treatment of the underlying inflammation and reduction of exacerbations are considered by both categories of physicians as primary objectives of the therapy. Interestingly, the PLATINO study, a multicenter population-based survey carried out in five Latin American cities, report that the COPD-Asthma overlap is associated with increased severity, as indicated by the higher risks for exacerbations and hospitalizations compared to those with COPD .
Both GPs and specialists believe that therapeutic continuity is of the essence for the achievement of clinical outcomes with all classes of drugs. The literature reports examples of clinical worsening and failure to achieve therapeutic objectives due to low compliance with continuous treatment. A post hoc analysis of the TORCH study demonstrated that compliance is associated with a significant reduction of the risk of death and hospitalization due to exacerbations in COPD patients, regardless of treatment . Another example is the observation that discontinuation of inhaled corticosteroid in patients with moderate-to-severe COPD stabilized with fluticasone/salmeterol combination led to a fast and significant deterioration of the function and symptoms and to increased exacerbations, confirming the role played by this class of drugs in the background treatment of COPD [23, 24].
In conclusion, a good knowledge and awareness of COPD has been observed in a high percentage of GPs. The frequent exacerbator phenotype is viewed by both specialists and GPs as the most prevalent in clinical practice, bearing a high risk of hospitalization. For specialists, therapeutic measures aimed at reducing the number and severity of exacerbations are primarily based on the combination of inhaled corticosteroid and bronchodilator, presumably because of the complementary pharmacological action of its components, whereas while GPs’ choices tend to be more diversified. Adherence to medication regimens is of the essence for the achievement of clinical outcomes.
- Global Initiative for Chronic Obstructive Lung Disease.http://www.goldcopd.com,
- Burrows B, Fletcher CM, Heard BE, Jones NL, Wootliff JS: The emphysematous and bronchial types of chronic airways obstruction. A clinicopathological study of patients in London and Chicago. Lancet. 1966, 1: 830-835.View ArticlePubMedGoogle Scholar
- Pistolesi M, Carmiciottoli G, Paoletti M, Marmai C, Lavorini F, Meoni E, Marchesi C, Giuntini C: Identification of a predominant COPD phenotype in clinical practice. Respir Med. 2008, 102: 367-376. 10.1016/j.rmed.2007.10.019.View ArticlePubMedGoogle Scholar
- Burgel PR, Paillasseur HL, Caillaud D, llie-Leblond I, Chanez P, Escamilla R, Court-Fortune I, Perez T, Carré P, Roche N, Initiatives BPCO Scientific Committee: Clinical COPD phenotypes: a novel approach using principal component and cluster analyses. Eur Respir J. 2010, 36: 531-539. 10.1183/09031936.00175109.View ArticlePubMedGoogle Scholar
- Weatherhall M, Travers J, Shirtcliff PM, Marsh SE, Williams MV, Nowitz MR, Aldington S, Beasley R: Distinct clinical phenotypes of airways disease defined by cluster analysis. Eur Respir J. 2009, 34: 812-818. 10.1183/09031936.00174408.View ArticleGoogle Scholar
- Garcia-Aymerich , Gomez FP, Benet M, Farrero E, Basagaña X, Gayete À, Paré C, Freixa X, Ferrer J, Ferrer A, Roca J, Gáldiz JB, Sauleda J, Monsó E, Gea J, Barberà JA, Agustí À, Antó JM, PAC-COPD Study Group: Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. Thorax. 2011, 66: 430-437. 10.1136/thx.2010.154484.View ArticlePubMedGoogle Scholar
- Agusti A, Calverley PMA, Celli R, Coxson HO, Edwards LD, Lomas DA, MacNee W, Miller BE, Rennard S, Silverman EK, Tal-Singer R, Wouters E, Yates JC, Vestbo J, Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators: Characterization of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010, 11: 122-136.PubMed CentralPubMedGoogle Scholar
- Hurst JR, Vestbo J, Anzueto , Locantore N, Müllerova H, Tal-Singer R, Miller B, Locantore N, Müllerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF, Wedzicha JA, Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators: Susceptibility to exacerbations in chronic obstructive pulmonary disease. N Engl J Med. 2010, 363: 1128-1138. 10.1056/NEJMoa0909883.View ArticlePubMedGoogle Scholar
- Fabbri LM, Beghé B, Agusti A: Cardiovascular mechanisms of death in severe COPD exacerbation: time to think and act beyond guidelines. Thorax. 2011, 66: 745-747. 10.1136/thoraxjnl-2011-200406.View ArticlePubMedGoogle Scholar
- Agusti A, Edward LD, Rennard SI: Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One. 2012, 7 (5): e37483-10.1371/journal.pone.0037483. doi:10.1371PubMed CentralView ArticlePubMedGoogle Scholar
- Maclay JD, McAllister DA, Johnston S, Raftis J, McGuinnes C, Deans A, Newby DE, Mills NL, MacNee W: Increased platelet activation in patients with stable and acute exacerbation of COPD. Thorax. 2011, 66: 769-774. 10.1136/thx.2010.157529.View ArticlePubMedGoogle Scholar
- Høiseth AD, Neukamm A, Karlsson BD, Omland T, Brekke PH, Søyseth V: Elevated high-sensitivity cardiac troponin T is associated with increased mortality after acute exacerbation of chronic obstructive pulmonary disease. Thorax. 2011, 66: 775-781. 10.1136/thx.2010.153122.View ArticlePubMedGoogle Scholar
- McAllister DA, Maclay JD, Mills NL, Leitch A, Reid P, Carruthers R, O’Connor J, McAlpine L, Chalmers G, Newby DE, Clark E, Macfarlane PW, Macnee W: Diagnosis of myocardial infarction following hospitalization for exacerbation of COPD. Eur Respir J. 2012, 39 (5): 1097-2103. 10.1183/09031936.00124811.View ArticlePubMedGoogle Scholar
- Chang CL, Robinson SC, Mills GD, Sullivan GD, Karalus NC, McLachlan JD, Hancox RJ: Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax. 2011, 66: 764-768. 10.1136/thx.2010.155333.View ArticlePubMedGoogle Scholar
- Bhatt SP, Nanda S, Kintzer JS: Arrhythmias as trigger for acute exacerbations of chronic obstructive pulmonary disease. Respir Med. 2012, 106: 1134-1138. 10.1016/j.rmed.2012.04.007.View ArticlePubMedGoogle Scholar
- Patel AR, Kowlessar BS, Donaldson GC, Mackay AJ, Singh R, George SN, Garcha DS, Wedzicha JA, Hurst JR: Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013, 188: 1091-1099. 10.1164/rccm.201306-1170OC.PubMed CentralView ArticlePubMedGoogle Scholar
- Dal Negro RW, Tognella S, Tosatto R, Dionisi M, Turco P, Donner CF: Costs of chronic obstructive pulmonary disease (COPD) in Italy: the SIRIO study (Social Impact of Respiratory Integrated Outcomes). Respir Med. 2008, 102: 92-101. 10.1016/j.rmed.2007.08.001.View ArticlePubMedGoogle Scholar
- Mahler DA, Wire P, Horstman D, Chang C-N, Yates J, Fisher T, Shah T: Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002, 166: 1084-1091. 10.1164/rccm.2112055.View ArticlePubMedGoogle Scholar
- Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H: Efficacy and safety of budesonide/formoterol in the management of COPD. Eur Respir J. 2003, 21: 74-81. 10.1183/09031936.03.00031402.View ArticlePubMedGoogle Scholar
- Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C, TRial of Inhaled Steroids ANd long-acting beta2 agonists study group: Combining salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial. Lancet. 2003, 361: 449-456. 10.1016/S0140-6736(03)12459-2.View ArticlePubMedGoogle Scholar
- Kardos P, Wencker M, Glaab T, Vogelmeier C: Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007, 175: 144-149. 10.1164/rccm.200602-244OC.View ArticlePubMedGoogle Scholar
- Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J, TORCH investigators: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007, 356 (8): 775-789. 10.1056/NEJMoa063070.View ArticlePubMedGoogle Scholar
- Wouters EF, Postma DS, Fokkens B, Hop WC, Prins J, Kuipers AF, Pasma HR, Hensing CA, Creutzberg EC, COSMIC (COPD and Seretide: a Multi-Center Intervention and Characterization) Study Group: Withdrawal of fluticasone propionate from combined fluticasone/salmeterol treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax. 2005, 60: 480-487. 10.1136/thx.2004.034280.PubMed CentralView ArticlePubMedGoogle Scholar
- Ferguson GT, Anzueto A, Fei R, Emmett A, Knobil K, Kalberg C: Effect of fluticasone propionate/salmeterol (250/50 mcg) or salmeterol (50 mcg) on COPD exacerbations. Respir Med. 2008, 102 (8): 1099-1108. 10.1016/j.rmed.2008.04.019. doi:10.1016/j.rmed.2008.04.019View ArticlePubMedGoogle Scholar
- Documento Intersocietario 2012 “La gestione clinica integrata della BPCO”:http://www.aimarnet.it/pdf/GestioneBPCO.pdf,
- Mannino DM, Thorn D, Swensen A, Holguin F: Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008, 32: 962-969. 10.1183/09031936.00012408.View ArticlePubMedGoogle Scholar
- Decramer M, Janssen W: Chronic obstructive pulmonary disease and comorbidities. Lancet Respir Med. 2013, 1: 73-83. 10.1016/S2213-2600(12)70060-7.View ArticlePubMedGoogle Scholar
- Soriano JB, Roche N, Cockcroft J, Rabe K, Kearney M, Brusselle G, Franssen F, Garcia Rio F, Lundbäck B, Marsden H, Muellerova H, Bloomfield P, Nadeau G, Vasselle M, Adams Z, Henderson A, Fabbri L: Prevalence and under-diagnosis of airflow limitation and other lung function abnormalities in patients with ischaemic heart disease: an interim analysis of the ALICE study. ERS Annual Congress Wien. 2012, abstr n.7254, Session 78Google Scholar
- Gibson PG, Simpson JL: The overlap syndrome of asthma and COPD: what are its features and how important is it?. Thorax. 2009, 64: 728-735. 10.1136/thx.2008.108027.View ArticlePubMedGoogle Scholar
- Melbye H, Drivenes E, Dalbak LG, Leinan T, Høegh-Henrichsen S, Ostrem A: Asthma, chronic obstructive pulmonary disease, or both? Diagnostic labeling and spirometry in primary care patients aged 40 years or more. Int J Chron Obstruct Pulmon Dis. 2011, 6: 597-603.PubMed CentralView ArticlePubMedGoogle Scholar
- Menezes AM, Montes de Oca M, Pérez-Padilla R, Nadeau G, Wehrmeister FC, Lopez-Varela MV, Muiño A, Jardim JR, Valdivia G, Talamo C, the PLATINO team: Increased risk of exacerbations and hospitalization in subjects with an overlap phenotype: COPD-asthma. Chest. 2014, 145: 297-304. 10.1378/chest.13-0622. doi:10.1378/chest.13-0622View ArticlePubMedGoogle Scholar
- Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC: Chronic obstructive pulmonary disease surveillance - United States, 1971–2000. MMWR Surveill Summ. 2002, 51 (6): 1-16.Google Scholar
- de Marco R, Accordini S, Cerveri I, Corsico A, Sunyer J, Neukirch F, Künzli N, Leynaert B, Janson C, Gislason T, Vermeire P, Svanes C, Anto JM, Burney P, European Community Respiratory Health Survey Study Group: An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. Thorax. 2004, 59 (2): 120-125. 10.1136/thorax.2003.011163.PubMed CentralView ArticlePubMedGoogle Scholar
- Sutherland ER, Cherniack RM: Management of chronic obstructive pulmonary disease. N Engl J Med. 2004, 350: 2689-2697. 10.1056/NEJMra030415.View ArticlePubMedGoogle Scholar
- Horne R: Compliance, adherence, and concordance: implications for asthma treatment. Chest. 2006, 130: 65S-72S. 10.1378/chest.130.1_suppl.65S.View ArticlePubMedGoogle Scholar
- Restrepo RD, Alvarez MT, Wittnebel LD, Sorenson H, Wettstein R, Vines DL, Sikkema-Ortiz J, Gardner DD, Wilkins RL: Medication adherence issues in patients treated for COPD. Int J Chron Obstruct Pulmon Dis. 2008, 3: 371-384.PubMed CentralPubMedGoogle Scholar
- Williams LK, Peterson EL, Wells K, Ahmedani BK, Kumar R, Burchard EG, Chowdhry VK, Favro D, Lanfear DE, Pladevall M: Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroids nonadherence. J Allergy Clin Immunol. 2011, 128: 1185-1191. 10.1016/j.jaci.2011.09.011.PubMed CentralView ArticlePubMedGoogle Scholar
- Baiardini , Braido , Giardini A, Majani G, Cacciola C, Rogaku A, Scordamaglia A, Canonica GW: Adherence to treatment: assessment of an unmet need in asthma. J Investig Allergol Clin Immunol. 2006, 16 (4): 218-223.PubMedGoogle Scholar
- Canonica GW, Baena-Cagnani CE, Blaiss MS, Dahl R, Kaliner MA, Valovirta EJ, GAPP Survey Working Group: Unmet needs in asthma: Global Asthma Physician and Patient (GAPP Survey): global adult findings. Allergy. 2007, 62: 668-674. 10.1111/j.1398-9995.2007.01352.x.View ArticlePubMedGoogle Scholar
- Lavorini F, Magnan A, Dubus JC, Voshaar T, Corbetta L, Broeders M, Dekhuijzen R, Sanchis J, Viejo JL, Barnes P, Corrigan C, Levy M, Crompton GK: Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med. 2008, 102: 593-604. 10.1016/j.rmed.2007.11.003.View ArticlePubMedGoogle Scholar
- Laube BL, Janssens HM, de Jongh FH, Devadason S, Dhand R, Diot P, Everard ML, Horvath I, Navalesi P, Voshaar T, Chrystyn H, European Respiratory Society; International Society for Aerosols in Medicine: What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 2011, 37: 1308-1331. 10.1183/09031936.00166410.View ArticlePubMedGoogle Scholar
- Albert P, Agusti A, Edward L, Tal-Singer R, Yates J, Bakke P, Celli BR, Coxson HO, Crim C, Lomas DA, Macnee W, Miller B, Rennard S, Silverman EK, Vestbo J, Wouters E, Calverley P: Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. Thorax. 2012, 67: 701-708. 10.1136/thoraxjnl-2011-201458.View ArticlePubMedGoogle Scholar
- Quint JK, Donaldson GC, Hurst JR, Goldring JJ, Seemungal TR, Wedzicha JA: Predictive accuracy of patient-reported exacerbation frequency in COPD. Eur Respir J. 2001, 37: 501-507.View ArticleGoogle Scholar
- Sin DD, Man SF: Why are patients with COPD at increased risk of cardiovascular disease? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003, 107: 1514-1519. 10.1161/01.CIR.0000056767.69054.B3.View ArticlePubMedGoogle Scholar
- Engstrom G, Lind P, Hedblad B, Wollmer P, stavenow L, Janzon L, Lindgärde F: Lung function and cardiovascular risk: relationship with inflammation-sensitive plasma proteins. Circulation. 2002, 106: 2555-2560. 10.1161/01.CIR.0000037220.00065.0D.View ArticlePubMedGoogle Scholar
- Anthonisen NR, Connet JE, Enright PL, Manfreda J, Lung Health Study Research Group: Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med. 2002, 166: 333-339. 10.1164/rccm.2110093.View ArticlePubMedGoogle Scholar
- Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Crim C, Willits LR, Yates JC, Vestbo J, TORCH Investigators: Cardiovascular events in patients with COPD: TORCH Study results. Thorax. 2010, 65: 719-725. 10.1136/thx.2010.136077.View ArticlePubMedGoogle Scholar
- Ferguson GT, Funck-Brentano C, Fisher T, Darken P, Reisner C: Cardiovascular safety of salmeterol in COPD. Chest. 2003, 123: 1817-1824. 10.1378/chest.123.6.1817.View ArticlePubMedGoogle Scholar
- Ferguson GT, Calverley PM, Anderson JA, Jenkins CR, Jones PW, Willits LR, Yates JC, Vestbo J, Celli B: Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health Study. Chest. 2009, 136: 1456-1465. 10.1378/chest.08-3016.View ArticlePubMedGoogle Scholar
- Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M, UPLIFT Study Investigators: A 4-year trial of tiotropium in chronic obstructive pulmonary diseases. N Engl J Med. 2008, 359: 1543-1554. 10.1056/NEJMoa0805800.View ArticlePubMedGoogle Scholar
- Vestbo J, Anderson JA, Calverley PM, Celli B, Ferguson GT, Jenkins C, Knobil K, Willits LR, Yates JC, Jones PW: Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax. 2009, 64: 939-943. 10.1136/thx.2009.113662.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.